XNASAXSM
Market cap4.00bUSD
Jan 08, Last price
82.57USD
1D
-1.44%
1Q
-0.61%
Jan 2017
1,123.26%
IPO
810.36%
Name
Axsome Therapeutics Inc
Chart & Performance
P/E
—
P/S
14.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.06%
Rev. gr., 5y
%
Revenues
271m
+440.80%
Net income
-239m
L+20.97%
CFO
-145m
L+24.52%
Earnings
Feb 18, 2025
Profile
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 270,600 440.80% | 50,037 | |||||||
Cost of revenue | 447,132 | 222,399 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (176,532) | (172,362) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 960 | 10,633 | |||||||
Tax Rate | |||||||||
NOPAT | (177,492) | (182,994) | |||||||
Net income | (239,238) 20.97% | (197,766) 46.56% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 258,750 | 236,256 | |||||||
BB yield | -7.16% | -7.53% | |||||||
| Debt | |||||||||
Debt current | 2,534 | 425 | |||||||
Long-term debt | 193,407 | 94,684 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 73,300 | 31,100 | |||||||
Net debt | (190,252) | (105,734) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (145,080) | (116,511) | |||||||
CAPEX | (582) | (702) | |||||||
Cash from investing activities | (582) | (53,702) | |||||||
Cash from financing activities | 331,013 | 284,582 | |||||||
FCF | (183,967) | (183,193) | |||||||
| Balance | |||||||||
Cash | 386,193 | 200,842 | |||||||
Long term investments | |||||||||
Excess cash | 372,663 | 198,340 | |||||||
Stockholders' equity | (835,566) | (596,328) | |||||||
Invested Capital | 1,287,482 | 831,668 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 45,425 | 40,656 | |||||||
Price | 79.59 3.19% | 77.13 104.16% | |||||||
Market cap | 3,615,393 15.29% | 3,135,793 120.64% | |||||||
EV | 3,425,141 | 3,030,059 | |||||||
EBITDA | (169,698) | (166,797) | |||||||
EV/EBITDA | |||||||||
Interest | 6,453 | 7,335 | |||||||
Interest/NOPBT | |||||||||